396 related articles for article (PubMed ID: 23376148)
21. Outcomes of collagenase Clostridium histolyticum in men with ventral curvatures: an updated series.
Larson H; Savage J; Brearton K; Warner R; Ziegelmann M; Kohler T; Trost L
J Sex Med; 2024 Jan; 21(2):169-174. PubMed ID: 38141054
[TBL] [Abstract][Full Text] [Related]
22. Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.
Gabrielson AT; Spitz JT; Hellstrom WJG
Sex Med Rev; 2018 Jan; 6(1):143-156. PubMed ID: 28454897
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.
Nguyen HMT; Anaissie J; DeLay KJ; Yafi FA; Sikka SC; Hellstrom WJG
J Sex Med; 2017 Oct; 14(10):1220-1225. PubMed ID: 28874331
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes.
Bajic P; Wiggins AB; Ziegelmann MJ; Levine LA
J Sex Med; 2020 May; 17(5):1005-1011. PubMed ID: 32127330
[TBL] [Abstract][Full Text] [Related]
25. Re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies: M. Gelbard, I. Goldstein, W. J. Hellstrom, C. G. McMahon, T. Smith, J. Tursi, N. Jones, G. J. Kaufman and C. C. Carson, III J Urol 2013; 190: 199-207.
Jain S; Mavuduru RM; Agarwal MM; Singh SK; Mandal AK
J Urol; 2014 Feb; 191(2):561-3. PubMed ID: 24239419
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of collagenase Clostridium histolyticum in Peyronie's disease following a modified treatment protocol.
García Cruz E; Mercader Barrull C; Camacho Rovira D; Alcaraz Asensio A
Actas Urol Esp (Engl Ed); 2021 Apr; 45(3):215-219. PubMed ID: 33531284
[TBL] [Abstract][Full Text] [Related]
27. Continuing Collagenase Clostridium Histolyticum Injections Among Initial Nonresponders Results in Significant Curvature Improvements in the Majority of Peyronie's Disease Men.
Alom M; Burgon H; Ziegelmann M; Köhler T; Helo S; Trost L
J Sex Med; 2021 Jun; 18(6):1092-1098. PubMed ID: 34020925
[TBL] [Abstract][Full Text] [Related]
28. Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie's disease using the modified shortened protocol: Results from a retrospective analysis.
Capece M; Arcaniolo D; Manfredi C; Palmieri A; De Sio M; Verze P; Fusco F; Longo N; Mirone V
Andrologia; 2020 Apr; 52(3):e13527. PubMed ID: 32003061
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Collagenase
Green B; Flores A; Warner J; Kohler T; Helo S; Trost L
J Urol; 2023 Nov; 210(5):791-802. PubMed ID: 37811752
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.
Alom M; Sharma KL; Toussi A; Kohler T; Trost L
J Sex Med; 2019 Jun; 16(6):891-900. PubMed ID: 30956106
[TBL] [Abstract][Full Text] [Related]
31. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.
Abdel Raheem A; Johnson M; Abdel-Raheem T; Capece M; Ralph D
Sex Med Rev; 2017 Oct; 5(4):529-535. PubMed ID: 28874327
[TBL] [Abstract][Full Text] [Related]
32. A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease results in reduced procedural morbidity using a standardized hematoma classification rubric.
Amighi A; Mills SA; Eleswarapu SV; Regets KV; Mendhiratta N; Mills JN
World J Urol; 2020 Feb; 38(2):293-298. PubMed ID: 31152197
[TBL] [Abstract][Full Text] [Related]
33. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Yang KK; Bennett N
Urology; 2016 Aug; 94():143-7. PubMed ID: 27211926
[TBL] [Abstract][Full Text] [Related]
34. Safety of Collagenase Clostridium histolyticum Injection Therapy for Peyronie Disease in Patients Continuing Antiplatelet or Anticoagulant Therapy.
Amighi A; Regets KV; Nork JJ; Mendhiratta N; Mills JN; Eleswarapu SV
J Sex Med; 2020 Feb; 17(2):353-356. PubMed ID: 31866126
[TBL] [Abstract][Full Text] [Related]
35. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
Abdel Raheem A; Capece M; Kalejaiye O; Abdel-Raheem T; Falcone M; Johnson M; Ralph OG; Garaffa G; Christopher AN; Ralph DJ
BJU Int; 2017 Nov; 120(5):717-723. PubMed ID: 28612401
[TBL] [Abstract][Full Text] [Related]
36. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
Jordan GH
J Sex Med; 2008 Jan; 5(1):180-7. PubMed ID: 18173766
[TBL] [Abstract][Full Text] [Related]
37. Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease.
Serefoglu EC; Smith TM; Kaufman GJ; Liu G; Yafi FA; Hellstrom WJG
Urology; 2017 Sep; 107():155-160. PubMed ID: 28554517
[TBL] [Abstract][Full Text] [Related]
38. Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie's Disease with Calcified Plaques.
Masterson TA; Atuluru P; Zucker I; Molina M; Ibrahim E; Nackeeran S; Kava B; Ramasamy R
Eur Urol Focus; 2023 Jan; 9(1):55-59. PubMed ID: 36272924
[TBL] [Abstract][Full Text] [Related]
39. Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease.
Anaissie J; Yafi FA; DeLay KJ; Traore EJ; Sikka SC; Hellstrom WJG
Urology; 2017 Feb; 100():125-130. PubMed ID: 27816605
[TBL] [Abstract][Full Text] [Related]
40. Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.
Hoy SM
Clin Drug Investig; 2020 Jan; 40(1):83-92. PubMed ID: 31628593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
